Abstract
30 subjects — 23 with amyotrophic lateral sclerosis (ALS), 4 with Charcot-Marie Tooth atrophy, 2 with progressive spinal muscle atrophy and 1 with radiation myelopathy —were given chronic low-dose TRH therapy. The effects of treatment were assessed on the scale of Norris et al. (1974). The outcome of the study, in agreement with some and at variance with other studies, was that TRH induced a statistically significant neurological improvement in 17 of the 23 ALS patients but little or none in the other ALS patients and in patients with other neurological diseases.
Sommario
30 soggetti di cui 23 affetti da Sclerosi Laterale Amiotrofica, 4 dalla malattia di Charcot-Marie-Tooth, 2 affetti da Amiotrofia Spinale Progressiva, 1 affetto, da una Mielopatia da Raggi X, sono stati sottoposti ad un trattamento cronico con basse dosi di TRH. Gli effetti della terapia sulle performances neurologiche sono stati valutati con la scala di Norris et al. (1974). I risultati dello studio, in parte in accordo, in parte in contrasto con quelli di precedenti studi, mostrano che il TRH induce un miglioramento, statisticamente significativo, delle performances neurologiche in 17 dei 23 pazienti con SLA mentre determina modificazioni insignificanti o nessuna modificazione nei restanti casi di SLA e nei soggetti affetti da altre malattie neurologiche.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bassiri RM., Utiger RD.:Metabolism and excretion of exogenous thyrotropin releasing hormone in humans. J. Clin. Invest 52:1616–1619, 1973.
Brooke MH. Florence JM., Heller SL., et al.:Controlled trial of thyrotropin releasing hormone in Amyotrophic Lateral Sclerosis. Neurology 36:146–151, 1986.
Caroscio JT., Cohen JA., Zawodniak J., et al:A double blind, placebo-controlled trial of TRH in Amyotrophic Lateral Sclerosis. Neurology 36:141–145, 1986.
Engel WK., Siddique T., Nicoloff JT.:Effect on weakness and spasticity in Amyotrophic Lateral Sclerosis of thyrotropin releasing hormone. Lancet 2:73–75, 1983.
Engel WK., Carlo JR. Van Der Bergh P., et al:Further clinical studies of TRH in ALS and other motor neuron disorders. Neurology 34, (suppl. 1): 238, 1984.
Engel WK., Siddique T.:Transient autorefractory state of transmitter like effect of thyrotropin releasing hormone in Amyotrophic Lateral Sclerosis: A new clinical phenomenon. Neurology 34, (suppl. 1): 147, 1984.
Engel WK., Spiel RH.:Prolonged at home treatment of motor neuron diseases with self alministered subcutaneous high-doses of TRH. Neurology 35, (suppl. 1): 106, 1985.
Fornarelli M., Delwaide PJ.:TRH and the upper motor neuron syndrome in man. In: Neuropeptides in human therapy: pharmacology and clinical perspectives of TRH-T. Ed. Drago F.: Florence 1987, pp 59–64.
Gracco VL., Caligiuri M., Abbs JH., et al. Placebo controlled computerized dynametric measurement of bulbar and somatic muscle strenght in patients with Amyotropic Lateral Sclerosis following intravenous infusion of 10 mg/Kg thyrotropin releasing hormone. Ann. Neurol. 16:110, 1984.
Idrisoglu H., Ozdemir G.:Motor neuron disease (ALS) and thyrotropin releasing hormone (TRH): the effect of repeated low dosage on muscle weakness and spasticity including TSH esponse to TRH. Int. Cong Therap Res Psychol: Aspects of ALS-Varese, 1985, Abs.
Imoto K., Saida K., Iwamura K., et al.:Amyotrophic Lateral Sclerosis: a double blind cross-over trial of thyrotropin releasing hormone. J. Neurol Neurosurg Psychiatry 47:1332–1334, 1984.
Jackson IMD., Munsat TL., Taft J., et al.:TRH is normal in ALS spinal cord, but cyclic His-Pro-DKP is elevated. Neurology 35, (suppl. 1): 106, 1985, Abs.
Jerusalem F., Fresman J:Comparison of treatment trials in Amyotrophic Lateral Sclerosis between thyrotropin releasing hormone (TRH) and the derivative-TRH. Int. Cong. Therap Res Psychol: Aspect of ALS-Varese, 1985, Abs.
Mitsumoto H., Salgado ED. Negrosky D., et al.:Amyotrophic Lateral Sclerosis: effects of acute intravenous and chronic subacutaneous administration of thyrotropin releasing hormone in controlled trials. Neurology 36:152–159, 1986.
Munsat TL., Mora Is., Robinton JE., et al.:Intrathecal thyrotropin releasing hormone in Amyotrophic Lateral Sclerosis: preliminary observations. Neurology 34, (suppl. 1):239, 1984.
Munsat TL., Taft J., Kasdon D.:Intrathecal thyrotropin releasing hormone in Amyotrophic Lateral Sclerosis. Neurol. Clin 5:159–170, 1987.
Norris FH., Calanchini Pr., Fallart RJ, et al.:The administration of guanidine in Amyotrophic Lateral Sclerosis. Neurology 24:721–722, 1974.
Pinelli P., Pisano F. An EMG study of the effects of TRH-T in degenerative progressive motorneuronopathies and multifocal neuropathy. In: Neuropeptides in human therapy: pharmacology and clinical perspectives of TRH-T. Drago F Ed.-Florence 1987, p 65.
Pinelli P., Miscio G., Pisano F., Picco D.:The effect of TRH in the degenerative diseases of the motor system. In: Protirelin tartrate (TRH-T). Pharmacological and clinical studies: recent advances and perspectives. Agnoli A., Delwaide PJ., Prangié AJ., Scapagnini U — Eds. John Libbey, London, 1988.
Pirola CJ., Balda MS., Finkielman S., Nahmod VE. Increase in muscarinic receptors in rat intestine by thyrotropin releasing hormone (TRH). Life Sci 34:1643–1649, 1984.
Prasad C, Matsui T., Peterkofskya:Antagonism of ethanol narcosis by histidylproline diketopiperazine. Nature 268:142–144, 1977.
Redding JW., Schally AV.:Studies on the inactivation of thyrotropin, releasing hormone (TRH). Proc. Soc Exp Biol. Med. 131: 415–419, 1069.
Saida T., Imoto K., Saida K., et al.:Trials of thyrotropin releasing hormone treatment of patients with Amyotrophic Lateral Sclerosis. Ann Neurol 16:109, 1984.
Serratrice G., Desnuelle C., Crevat A., et al.:Traitement de la Sclérose Latérale Amyotrophique par le facteur de libération de l'hormone thyréotrope (TRH). Rev Neurol 142:133–139, 1986.
Sobue I., Yamamoto H., Honagaya M., et al.:Effect of thyrotropin releasing hormone on ataxia of spinocerebellar degeneration. Lancet i, 418, 1980.
Stober T., Schimrigk K., Dietzch S., et al.:Intrathecal thyrotropin releasing hormone therapy of Amyotrophic Lateral Sclerosis. J. Neurol. 232:13–14, 1985.
Sufit R., Beaulieu D., Sangup M., et al.:Placebo controlled quantitative measurements of neuromuscular function following intravenous infusion of 10 mg/kg thyrotropin releasing hormone in 16 male patients with Amyotrophic Lateral Sclerosis. Ann. Neurol. 16:110–111, 1984.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Congia, S., Tronci, S., Ledda, M. et al. Low doses of TRH in amyotrophic lateral sclerosis and in other neurological diseases. Ital J Neuro Sci 12, 193–198 (1991). https://doi.org/10.1007/BF02337033
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02337033